Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H39N6O9P |
Molecular Weight | 658.6392 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NC(N)=NC2=C1N=CN2[C@@H]3O[C@H](COP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC4=CC=CC5=C4C=CC=C5)[C@@H](O)[C@@]3(C)O
InChI
InChIKey=YFXGICNMLCGLHJ-RSKRLRQZSA-N
InChI=1S/C30H39N6O9P/c1-17(26(38)42-15-29(2,3)4)35-46(40,45-20-13-9-11-18-10-7-8-12-19(18)20)43-14-21-23(37)30(5,39)27(44-21)36-16-32-22-24(36)33-28(31)34-25(22)41-6/h7-13,16-17,21,23,27,37,39H,14-15H2,1-6H3,(H,35,40)(H2,31,33,34)/t17-,21+,23+,27+,30+,46?/m0/s1
BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor was developed for the treatment of hepatitis C. Drug participated in phase II clinical trials to evaluate its safety and tolerability. However, in 2012 Bristol-Myers Squibb announced discontinues the development due to safety reasons. The U.S. Food and Drug Administration (FDA) subsequently placed BMS-986094 on clinical hold.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01425970
Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000175091
Created by
admin on Sat Dec 16 01:28:34 GMT 2023 , Edited by admin on Sat Dec 16 01:28:34 GMT 2023
|
PRIMARY | |||
|
46700744
Created by
admin on Sat Dec 16 01:28:34 GMT 2023 , Edited by admin on Sat Dec 16 01:28:34 GMT 2023
|
PRIMARY | |||
|
DB11966
Created by
admin on Sat Dec 16 01:28:34 GMT 2023 , Edited by admin on Sat Dec 16 01:28:34 GMT 2023
|
PRIMARY | |||
|
1234490-83-5
Created by
admin on Sat Dec 16 01:28:34 GMT 2023 , Edited by admin on Sat Dec 16 01:28:34 GMT 2023
|
PRIMARY | |||
|
62F4AD749Y
Created by
admin on Sat Dec 16 01:28:34 GMT 2023 , Edited by admin on Sat Dec 16 01:28:34 GMT 2023
|
PRIMARY | |||
|
DTXSID00154017
Created by
admin on Sat Dec 16 01:28:34 GMT 2023 , Edited by admin on Sat Dec 16 01:28:34 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD